EG24019A - Optimised formulation of tobramycin for aerosolization - Google Patents

Optimised formulation of tobramycin for aerosolization

Info

Publication number
EG24019A
EG24019A EG2002060744A EG2002060744A EG24019A EG 24019 A EG24019 A EG 24019A EG 2002060744 A EG2002060744 A EG 2002060744A EG 2002060744 A EG2002060744 A EG 2002060744A EG 24019 A EG24019 A EG 24019A
Authority
EG
Egypt
Prior art keywords
aerosolization
tobramycin
formulation
optimised
optimised formulation
Prior art date
Application number
EG2002060744A
Other languages
English (en)
Inventor
Chiara Malvolti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177921&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24019(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Application granted granted Critical
Publication of EG24019A publication Critical patent/EG24019A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EG2002060744A 2001-07-02 2002-06-29 Optimised formulation of tobramycin for aerosolization EG24019A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01116071A EP1273292B1 (de) 2001-07-02 2001-07-02 Optimierte Tobramycin-Formulierung zur Aerosolbildung

Publications (1)

Publication Number Publication Date
EG24019A true EG24019A (en) 2008-03-25

Family

ID=8177921

Family Applications (1)

Application Number Title Priority Date Filing Date
EG2002060744A EG24019A (en) 2001-07-02 2002-06-29 Optimised formulation of tobramycin for aerosolization

Country Status (26)

Country Link
US (5) US6987094B2 (de)
EP (1) EP1273292B1 (de)
JP (1) JP4262086B2 (de)
KR (1) KR100910888B1 (de)
CN (1) CN1234346C (de)
AT (1) ATE267591T1 (de)
AU (1) AU2002319226B2 (de)
BG (1) BG66328B1 (de)
BR (1) BRPI0211320B8 (de)
CA (1) CA2452638C (de)
CZ (1) CZ299348B6 (de)
DE (1) DE60103527T2 (de)
DK (1) DK1273292T3 (de)
EA (1) EA006068B1 (de)
EE (1) EE05392B1 (de)
EG (1) EG24019A (de)
ES (1) ES2222294T3 (de)
HU (1) HU230807B1 (de)
PL (1) PL202598B1 (de)
PT (1) PT1273292E (de)
SI (1) SI1273292T1 (de)
SK (1) SK285806B6 (de)
TN (1) TNSN03149A1 (de)
TR (1) TR200401980T4 (de)
WO (1) WO2003004005A1 (de)
ZA (1) ZA200400026B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
TR200401980T4 (tr) * 2001-07-02 2004-09-21 Chiesi Farmaceutici S.P.A. Aerosol olarak uygulama için en uygun hale getirilmiş tobramisin formülasyonu
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
ES2342463T3 (es) * 2002-03-01 2010-07-07 Chiesi Farmaceutici S.P.A. Formulacion superfina de formoterol.
NZ546821A (en) * 2003-10-15 2009-04-30 Pari Pharma Gmbh Liquid preparation containing tobramycin
US8442280B2 (en) * 2004-01-21 2013-05-14 Edda Technology, Inc. Method and system for intelligent qualitative and quantitative analysis of digital radiography softcopy reading
ES2388420T3 (es) * 2004-05-17 2012-10-15 Gilead Sciences, Inc. Combinación de fosfomicina/aminoglucósido aerosolizada para el tratamiento de las infecciones respiratorias bacterianas
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) * 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
WO2007041156A2 (en) 2005-09-29 2007-04-12 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
US20090246146A1 (en) * 2008-01-25 2009-10-01 Botond Banfi Halides in the treatment of pathogenic infection
KR101959873B1 (ko) 2008-10-07 2019-03-19 랩터 파마슈티컬스 인코포레이티드 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형
CA2739893C (en) * 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
JP5960434B2 (ja) * 2009-02-18 2016-08-02 アラダイム コーポレーション 肺送達のためのｐＨ調節された製剤
WO2011029059A1 (en) 2009-09-04 2011-03-10 Mpex Pharmaceuticals, Inc. Use of aerosolized levofloxacin for treating cystic fibrosis
EP2388008A1 (de) 2010-05-14 2011-11-23 Combino Pharm, S.L. Stabile, konservierungsmittelfreie, wässrige Formulierung zur Verabreichung durch Aerosolisierung enthaltend Tobramycin
KR102012418B1 (ko) 2010-07-12 2019-08-20 셀리아 파마슈티칼즈 에이피에스 에어로졸화에 의한 토브라마이신의 투여에 의한 폐 감염의 치료
JP5922660B2 (ja) * 2010-09-13 2016-05-24 ユニバーシティ・オブ・チューリッヒＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｚｕｒｉｃｈ 細菌感染性疾患の処置
WO2012106382A1 (en) * 2011-01-31 2012-08-09 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
ES2532667T3 (es) 2011-09-12 2015-03-30 Meiji Seika Pharma Co., Ltd. Composiciones acuosas que contienen arbekacina
GB201208080D0 (en) 2012-05-09 2012-06-20 Norton Healthcare Ltd Tobramycin formulation
US12226407B2 (en) 2012-07-24 2025-02-18 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CN105534961B (zh) * 2015-12-30 2019-06-04 孙红娟 妥布霉素吸入溶液及其制备方法
CN105616345B (zh) * 2016-03-01 2018-08-21 上海方予健康医药科技有限公司 一种妥布霉素吸入组合物及其制备方法和用途
EP3551191A4 (de) * 2016-12-09 2020-09-09 EnBiotix, Inc. Aminoglykosid-potenzierung zur behandlung von pulmonaler bakterieller infektion
CN108014099B (zh) * 2017-12-15 2019-03-01 武汉兴华智慧医药科技有限公司 一种吸入用妥布霉素溶液及其制备方法
GB2565941A (en) * 2018-11-27 2019-02-27 Norton Healthcare Ltd A process for preparing a formulation
CN113018443B (zh) * 2019-12-27 2022-09-13 海南斯达制药有限公司 治疗呼吸系统疾病的药物组合物及其制备方法
CN113952320B (zh) * 2021-09-18 2022-03-18 健康元药业集团股份有限公司 一种包含妥布霉素吸入溶液的药物组件及其用途

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) * 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3622053A (en) * 1969-12-10 1971-11-23 Schering Corp Aerosol inhaler with flip-up nozzle
MX3864E (es) 1975-05-27 1981-08-26 Syntex Corp Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
US4185100A (en) * 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4499108A (en) * 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
US4584320A (en) * 1985-01-03 1986-04-22 David Rubin Anti-asthmatic composition and method using 8,11,14,17-eicosatetraenoic acid
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
AU8642391A (en) 1990-12-19 1992-07-22 Smithkline Beecham Corporation Aerosol formulations
US6006745A (en) * 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DK0585379T3 (da) 1991-05-21 1999-06-21 Abbott Lab Aerosol-inhalationsindretning
CZ282972B6 (cs) * 1991-08-29 1997-11-12 Broncho-Air Medizintechnik Ag Lékařský přístroj pro inhalování dávkovaných aerosolů
NZ244439A (en) 1991-09-25 1994-01-26 Fisons Plc Pressurised aerosol compositions comprising hydrofluoroalkane, dispersed
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
JP3908269B2 (ja) 1991-12-18 2007-04-25 スリーエム カンパニー 懸濁エアゾール製剤
DE4230876A1 (de) * 1992-03-17 1993-09-23 Asta Medica Ag Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
ATE177941T1 (de) * 1992-12-09 1999-04-15 Boehringer Ingelheim Pharma Stabilisierte medizinische aerosollösungen
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
AU4066693A (en) 1992-12-23 1994-07-19 Bernhard Hugemann Compacted drug body for use in the mechanical generation of inhalable active-substance particles
ES2122261T3 (es) 1993-03-17 1998-12-16 Minnesota Mining & Mfg Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester.
ES2107203T3 (es) 1993-03-17 1997-11-16 Minnesota Mining & Mfg Una formulacion de aerosol que contiene un adyuvante de dispersion derivado de un diol-diacido.
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
PT735884E (pt) * 1993-12-20 2000-09-29 Minnesota Mining & Mfg Formulacoes de aerossol de flunisolida
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
GB9425160D0 (en) 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
EE9700138A (et) 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
TR199701170T1 (xx) 1995-04-14 1998-02-21 Glaxo Wellcome Inc. Beklometazon dipropionat i�in �l��lm�� doz inhaleri.
HU219899B (hu) * 1995-04-14 2001-09-28 Glaxo Wellcome Inc. Inhalálóberendezés flutikaszon-propionát adagolására mért dózisban
TR199701169T1 (xx) * 1995-04-14 1998-03-21 Glaxo Wellcome Inc. Salmeterol i�in �l��lm�� doz inhaleri.
HU219900B (hu) * 1995-04-14 2001-09-28 Glaxo Wellcome Inc. Mért dózist adagoló inhalálóberendezés
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
JP2000514085A (ja) 1996-07-08 2000-10-24 ローヌ―プーラン・ロウラー・リミテッド 医薬シクロスポリンａエーロゾル溶液処方物
AU3811897A (en) 1996-07-24 1998-02-10 Oglios Therapeutics, Inc. Antisense oligonucleotides as antibacterial agents
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9620187D0 (en) 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
DE69734017T2 (de) 1996-12-04 2006-06-14 Link Products Ltd Arzneimittelzusammensetzungen und vorrichtungen zu deren verabreichung
US6413496B1 (en) * 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
JP2001511160A (ja) * 1997-02-05 2001-08-07 ヤゴ リサーチ アクチェンゲゼルシャフト 医学用エアゾール配合物
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
GB2326334A (en) 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
BR7702049U (pt) 1997-09-05 1999-09-14 Chiesi Farma Spa Bico pulverizador para utilização em inalador oral para medicamentos aerossóis
US5954047A (en) * 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
US6045784A (en) * 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
PL200941B1 (pl) * 1998-11-13 2009-02-27 Jagotec Ag Suchy proszkowy preparat inhalacyjny
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6290930B1 (en) * 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
AU2000250701B2 (en) * 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
TR200401980T4 (tr) * 2001-07-02 2004-09-21 Chiesi Farmaceutici S.P.A. Aerosol olarak uygulama için en uygun hale getirilmiş tobramisin formülasyonu
EP1340492A1 (de) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosolformulierungen zur pulmonalen Verabreichung von Arzneimitteln mit systemischer Wirkung
ES2342463T3 (es) * 2002-03-01 2010-07-07 Chiesi Farmaceutici S.P.A. Formulacion superfina de formoterol.
EP1415647A1 (de) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. Langwirkende beta-2-Agonisten in ultrafeiner Formulierung
US20050083693A1 (en) * 2003-10-21 2005-04-21 Timothy Garrett Flag illumination fixture

Also Published As

Publication number Publication date
TNSN03149A1 (en) 2005-12-23
CN1529589A (zh) 2004-09-15
PT1273292E (pt) 2004-10-29
SK16432003A3 (sk) 2004-06-08
DE60103527T2 (de) 2005-06-16
US20100098642A1 (en) 2010-04-22
EE200400050A (et) 2004-04-15
BG108475A (en) 2005-02-28
SI1273292T1 (en) 2004-12-31
JP2004535454A (ja) 2004-11-25
PL367139A1 (en) 2005-02-21
US20040186064A1 (en) 2004-09-23
WO2003004005A1 (en) 2003-01-16
BR0211320A (pt) 2004-09-28
CA2452638A1 (en) 2003-01-16
HU230807B1 (hu) 2018-06-28
US20120184502A1 (en) 2012-07-19
JP4262086B2 (ja) 2009-05-13
KR20040018403A (ko) 2004-03-03
EP1273292B1 (de) 2004-05-26
PL202598B1 (pl) 2009-07-31
EE05392B1 (et) 2011-04-15
HUP0400387A2 (hu) 2004-09-28
US6987094B2 (en) 2006-01-17
BRPI0211320B8 (pt) 2021-05-25
AU2002319226B2 (en) 2006-07-06
US7939502B2 (en) 2011-05-10
SK285806B6 (sk) 2007-08-02
DK1273292T3 (da) 2004-10-04
EA200301305A1 (ru) 2004-06-24
CA2452638C (en) 2010-10-05
HK1068784A1 (en) 2005-05-06
US7696178B2 (en) 2010-04-13
US8168598B2 (en) 2012-05-01
ATE267591T1 (de) 2004-06-15
US20050163722A1 (en) 2005-07-28
US20110212912A1 (en) 2011-09-01
ES2222294T3 (es) 2005-02-01
ZA200400026B (en) 2005-03-30
BRPI0211320B1 (pt) 2015-08-18
DE60103527D1 (de) 2004-07-01
CZ20033580A3 (cs) 2004-10-13
KR100910888B1 (ko) 2009-08-05
TR200401980T4 (tr) 2004-09-21
CN1234346C (zh) 2006-01-04
CZ299348B6 (cs) 2008-06-25
EP1273292A1 (de) 2003-01-08
BG66328B1 (bg) 2013-06-28
EA006068B1 (ru) 2005-08-25

Similar Documents

Publication Publication Date Title
EG24019A (en) Optimised formulation of tobramycin for aerosolization
PT1363600E (pt) Formulações líquidas para a prevenção e para o tratamento de doenças e distúrbios das mucosas
WO2001089496A3 (en) Compositions and methods for treating otic, ophthalmic and nasal infections comprising quinolone antibiotics
BR0012750A (pt) Agente de limpeza para superfìcies cerâmicas vìtreas
DE69511374D1 (de) Neue und verbesserte aminoglykosidformulierung als aerosol
LU91851I2 (fr) Aztréonam, pas en composition avec l'arginine, ou un sel pharmaceutiquement acceptable de l'aztréonam autre qu'un sel d'origine en particulier l'aztréonam lysine
NZ631469A (en) Aerosol fluoroquinolone formulations for improved pharmacokinetics
MX2010012452A (es) Suministro pulmonar de una fluoro-quinolona.
TW200612971A (en) Method for preventing or treating respiratory infections and acute otitis media in infants
AR043863A1 (es) Composiciones que contienen piperacilina y tazobactam, utiles para inyeccioines
EP1560488A4 (de) Antibakterielle mittel
DE60307860D1 (de) Aminocyclohexenchinoline und ihre azaisosterischen analoga mit antibakterieller wirkung
DE69831816D1 (de) Bakterizide desinfizierende peressigsäure-zusammensetzung
BRPI0411050A (pt) composições para prevenção e tratamento de sintomas semelhantes a gripe e resfriado compreendendo zinco quelado
AU2003303956A1 (en) Antibacterial agents
YU102503A (sh) Kondenzovani pirimidinski dhfr inhibitori kao antibakterijska sredstva
WO2003032985A3 (en) Concomitant oral and topical administration of anti - infective agents
ES2133722T3 (es) Utilizacion de dextranos simples o conjugados para la fabricacion de un medicamento para prevenir o reducir el riesgo de infeccion de germenes patogenos bacterianos.
EP1567520A4 (de) Chinoline und stickstoffhaltige derivatedavon und deren verwendung als antibakterielle mittel
WO2006033713A3 (en) Methods for ciprofloxacin inhalation
DK1157688T3 (da) Antibakterielle vandige ophthalmiske formuleringer med ofloxacin og chitosan
WO2018107020A8 (en) Aminoglycoside potentiation for treatment of pulmonary bacterial infection
UA27643U (en) Method for treatment of community-acquired pneumonia in children
TW200503734A (en) New use of soluble p-selectin and anthrax lethal toxin